Doravirine's evidence base is smaller than for older drugs and unusually focused, because it was developed to answer specific questions about tolerability and lipids rather than about effectiveness alone.
What did DRIVE-FORWARD test?
Doravirine against boosted darunavir in people starting treatment. It matched darunavir on viral suppression while producing significantly better lipid results, with lower cholesterol and triglycerides at forty-eight weeks.
What did DRIVE-AHEAD test?
Doravirine against efavirenz, both within single-tablet regimens. Suppression was comparable, and neuropsychiatric adverse events were substantially less frequent on doravirine: fewer vivid dreams, less dizziness and less disturbed sleep.
Why did that matter?
Because efavirenz was effective and widely discontinued for exactly those reasons. Demonstrating that a drug in the same class could avoid them was the entire purpose of developing doravirine.
What did DRIVE-SHIFT show?
That people already suppressed on a boosted regimen could switch to doravirine and maintain suppression, with improvements in lipids. That established it as a switch option rather than only for people starting treatment.
What does the resistance data show?
It retains activity against several common non-nucleoside mutations, including some that defeat efavirenz. Treatment-emergent resistance occurred in trials at low but non-zero rates, which is the expected pattern for this class.
How does its barrier compare?
Lower than integrase inhibitors and boosted protease inhibitors. This is the main reason it is not usually first choice, and it matters most for people whose dosing is likely to be irregular.
What about the lipid finding specifically?
Consistent across studies. Doravirine produced lower LDL and triglycerides than both comparators, and switching to it from a boosted regimen improved lipids. Whether that translates into fewer cardiovascular events over decades has not been directly demonstrated.
What about weight?
Reported changes have been modest compared with integrase inhibitors. For someone concerned about weight gain on an integrase-based regimen, that is a relevant point of comparison.
What about kidney and bone effects?
None attributable to doravirine. The combination tablet contains tenofovir disoproxil, which carries the usual kidney and bone considerations for that drug rather than for this one.
How long has it been in use?
Since the late 2010s, so the real-world record is shorter than for efavirenz or dolutegravir. The trial data are solid and the long-term picture is still accumulating.
What does real-world data show?
Broadly consistent with the trials, with good tolerability and low discontinuation. Uptake has been modest because integrase inhibitors occupy the first-line position, so the observational dataset is smaller.
What about pregnancy?
Data are limited, which is why it is not generally a first choice in pregnancy. That reflects absence of evidence rather than evidence of a problem.
What is still being studied?
Its use in switch and simplification strategies, and longer-term metabolic outcomes. Its core properties are established.
Where can you read the evidence yourself?
NAM aidsmap summarises HIV research reliably, and the British HIV Association publishes the guidelines UK clinicians follow. Both are freely available and considerably more useful than a general search.
How should you read a headline about it?
Carefully. Reports about antiretrovirals often describe single studies, early findings or practice in other countries. Checking a claim against NAM aidsmap, or asking your clinic, is quicker than assessing the study design yourself.
Do guidelines change quickly?
Deliberately slowly. Recommendations shift when several studies point the same way rather than after one result. If something you read about doravirine seems to contradict what you were told, ask before acting on it.
What has not been established?
Outcomes over several decades, in most cases, simply because the follow-up does not yet exist. That is a reason monitoring continues rather than a warning, and it applies to almost every modern antiretroviral.
Does the evidence apply to you?
Trials recruit particular populations and transfer best to people who resemble them. Where a study excluded a group, that is a gap rather than a negative finding, and it is fair to ask what your clinician's recommendation actually rests on.